During the last session, Novavax, Inc. (NASDAQ:NVAX)’s traded shares were 2.56 million, with the beta value of the company hitting 2.04. At the end of the trading day, the stock’s price was $11.40, reflecting an intraday gain of 2.43% or $0.27. The 52-week high for the NVAX share is $23.86, that puts it down -109.3 from that peak though still a striking 69.04% gain since the share price plummeted to a 52-week low of $3.53. The company’s market capitalization is $1.83B, and the average intraday trading volume over the past 10 days was 4.15 million shares, and the average trade volume was 9.91 million shares over the past three months.
Novavax, Inc. (NVAX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.60. NVAX has a Sell rating from 0 analyst(s) out of 16 analysts who have looked at this stock. 6 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 10 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.89.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Novavax, Inc. (NASDAQ:NVAX) trade information
Novavax, Inc. (NVAX) registered a 2.43% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.43% in intraday trading to $11.40, hitting a weekly high. The stock’s 5-day price performance is -4.68%, and it has moved by -11.01% in 30 days. Based on these gigs, the overall price performance for the year is 37.35%. The short interest in Novavax, Inc. (NASDAQ:NVAX) is 30.5 million shares and it means that shorts have 3.89 day(s) to cover.
The consensus price target of analysts on Wall Street is $31, which implies an increase of 63.23% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $19 and $174 respectively. As a result, NVAX is trading at a discount of -1426.32% off the target high and -66.67% off the low.
Novavax, Inc. (NVAX) estimates and forecasts
Statistics show that Novavax, Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Novavax, Inc. (NVAX) shares have gone up 130.77% during the last six months, with a year-to-date growth rate more than the industry average at 87.25% against 18.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 29.40% this quarter and then jump 75.70% in the quarter after that. In the rating firms’ projections, revenue will decrease -24.80% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 67.02M as predicted by 4 analyst(s). Meanwhile, a consensus of 4 analyst(s) estimates revenue growth to 163.55M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 186.99M and 291.34M respectively. In this case, analysts expect current quarter sales to shrink by -64.20% and then drop by -43.90% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 11.55%. While earnings are projected to return 81.70% in 2024, the next five years will return 37.90% per annum.
NVAX Dividends
Novavax, Inc. is due to release its next quarterly earnings in September. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Novavax, Inc. (NASDAQ:NVAX)’s Major holders
Novavax, Inc. insiders own 4.38% of total outstanding shares while institutional holders control 53.76%, with the float percentage being 56.23%. VANGUARD GROUP INC is the largest shareholder of the company, while 308.0 institutions own stock in it. As of 2024-06-30, the company held over 14.08 million shares (or 10.0599% of all shares), a total value of $178.19 million in shares.
The next largest institutional holding, with 11.85 million shares, is of BLACKROCK INC.’s that is approximately 8.4669% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $149.98 million.
Also, the Mutual Funds coming in first place with the largest holdings of Novavax, Inc. (NVAX) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . Data provided on Mar 31, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 3.55 shares. This amounts to just over 2.22 percent of the company’s overall shares, with a $40.46 million market value. The same data shows that the other fund manager holds slightly less at 3.44, or about 2.15% of the stock, which is worth about $39.24 million.
